External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.

Autor: Boyne DJ; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: devon.boyne1@ucalgary.ca., Chua N; Department of Medical Oncology and Hematology, Cross Cancer Institute, Edmonton, AB, Canada., Owen C; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Joe-Uzuegbu O; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Shakir H; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Gogna P; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Jarada TN; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Brenner DR; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Community Health Science, University of Calgary, Calgary, AB, Canada., Elia-Pacitti J; Janssen Inc., Toronto, ON, Canada., Ewara EM; Janssen Inc., Toronto, ON, Canada., Cheung WY; Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Sep; Vol. 23 (9), pp. e277-e285. Date of Electronic Publication: 2023 May 29.
DOI: 10.1016/j.clml.2023.05.013
Abstrakt: Background: The Follicular lymphoma international prognostic index (FLIPI) risk score and POD24 have previously been shown to have prognostic value in follicular lymphoma (FL), but the extent to which they can inform prognosis at the time of subsequent relapse is uncertain.
Patients and Methods: We conducted a longitudinal cohort study of individuals diagnosed with FL between 2004 and 2010 in Alberta, Canada who received front-line therapy and subsequently relapsed. FLIPI covariates were measured prior to the initiation of front-line therapy. Median overall survival (OS), progression-free survival (PFS2), and time to next treatment (TTNT2) were estimated from the time of relapse.
Results: A total of 216 individuals were included. The FLIPI risk score was highly prognostic at the time of relapse for OS (c-statistic = 0.70; HR [High vs. Low]  = 7.38; 95% CI: 3.05-17.88), PFS2 (c-statistic = 0.68; HR [High vs. Low]  = 5.84; 95% CI: 2.93-11.62) and TTNT2 (c-statistic = 0.68; HR [High vs. Low]  = 5.72; 95% CI: 2.87-11.41). POD24 was not prognostic at the time of relapse for either OS, PFS2, or TTNT2 (c-statistic = 0.55).
Conclusion: The FLIPI score measured at diagnosis may help with the risk stratification of individuals with relapsed FL.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: